T-knife Therapeutics is a T-cell receptor (TCR) company building a pipeline of innovative therapeutics for solid tumor patients and their families.  ​

We are leveraging our proprietary, transgenic mouse platform in order to discover fully-human TCRs, naturally selected in vivo for optimal affinity and specificity.​

We then develop novel, best-in-class TCR therapies that target tumor-specific antigens in multiple, difficult to treat solid tumor indications.​